2 more firms seek FDA nod on COVID-19 vaccines
Two new applications—one for monovalent and the other for bivalent vaccines—are pending with the Food and Drug Administration (FDA) for their commercial use against COVID-19, according to Director General Samuel Zacate.
The FDA chief, however, did not elaborate. So far, only Pfizer’s bivalent vaccine under the brand name Comirnaty Original/Omicron BA.4-5 was given the certificate of product registration, a license issued by the FDA for the commercial distribution and sale of a medical device.
The FDA is hoping Pfizer can finally bring in commercial batches of bivalent vaccine Tozinameran Famtozinameran by the end of this month or in August, Zacate said.
The jabs may be sold to consumers 12 years old and above and administered by a medical professional as a booster shot. —Kathleen de Villa
RELATED STORY:
Bivalent COVID-19 jabs need prescription – FDA
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
